Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Innospace's rocket crashes in first commercial launch in Brazil; shares tumble - 2The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- 3Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- 45 things for parents to know about changes to kids vaccine schedule
- 5Wedding trip Objections in Europe
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- 21 Things You Ought to Never Share with Your Childless Companion
- In the background: Visiting Notable Film Areas All over the Planet
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Brazil's Bolsonaro to continue his sentence at home because of poor health
